+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Blood Brain Barrier Market, 3rd Edition - Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Route of Administration, Target Disease Indication, Therapeutic Area and Key Geographical Regions

  • PDF Icon

    Report

  • 375 Pages
  • September 2024
  • Region: Global
  • Roots Analysis
  • ID: 5025060

The Blood Brain Barrier Market is valued at USD 36 million in 2024 growing at a CAGR of 49% during the forecast period 2024-2035.

The focus of blood-brain barrier drugs and technologies is to address the challenges posed by the selective nature of the blood-brain barrier, enabling therapeutic agents to reach the brain directly. Recent years have seen increased research and investment to understand and overcome these challenges, driven by rising incidences of neurological diseases like Alzheimer's and Parkinson's. This trend is expected to drive demand for therapies that bypass the blood-brain barrier, fostering innovation and expanding the market in this area. Innovations include drug delivery systems, nanoparticles, and medical devices aimed at enhancing treatment efficacy for neurological disorders by improving drug transport across the blood-brain barrier.

According to a study by the World Health Organization (WHO), diseases affecting the central nervous system (CNS) such as Alzheimer’s disease, brain cancer, multiple sclerosis, Parkinson’s disease, and stroke have a significant unmet need for effective treatments. Neurological disorders are the second leading cause of death and the foremost cause of disability worldwide. In 2021, it was reported that nearly 3.4 billion people globally suffer from CNS disorders, with over 6 million people living with Alzheimer’s, a figure expected to nearly double by 2050. In the US, nearly one million people are affected by Parkinson’s disease, with approximately 90,000 new diagnoses annually.

Extensive research and development efforts have yielded a variety of versatile blood-brain barrier technologies designed to enhance the permeability of the barrier or improve the brain-penetrating capabilities of pharmacological treatments. These advancements have attracted numerous new players to the field, suggesting significant growth potential in the years ahead.

Currently, the blood-brain barrier market is largely driven by technology licensing activities, as drug developers collaborate with platform providers to advance their therapeutic pipelines.

Key Market Segments

Type of Molecule

  • Small Molecules
  • Biologics

Target Disease Indication

  • Multiple Sclerosis
  • Amyotrophic Lateral Sclerosis
  • Mucopolysaccharidosis Type II (Hunter Syndrome)
  • Leptomeningeal Carcinomatosis
  • Mucopolysaccharidosis Type III A (Sanfilippo Syndrome A)

Route of Administration

  • Oral
  • Intravenous

Therapeutic Area

  • Neurodegenerative Disorders
  • Lysosomal Storage Disorders
  • Neuro-Oncology Disorders

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Research Coverage:

  • This chapter begins with an overview of the blood-brain barrier, discussing its importance in light of the increasing prevalence of neurological disorders. It covers various strategies for delivering drugs to the central nervous system (CNS), including both invasive and non-invasive techniques. The chapter also delves into the complexities of penetrating the blood-brain barrier and delivering drugs effectively to the CNS, highlighting the associated challenges.
  • The chapter offers a comprehensive introduction to essential concepts concerning the structure of the human brain, its components, and their roles within the central nervous system (CNS). It extensively covers both invasive and non-invasive methods utilized for drug delivery to the CNS. Additionally, it provides a detailed overview of the blood-brain barrier, tracing its historical development and emphasizing its crucial role in facilitating effective drug delivery amid the rising incidence of neurological disorders. The chapter further explores prominent strategies employed to develop drugs and technologies capable of crossing the blood-brain barrier or circumventing it. Finally, it addresses the primary challenges associated with utilizing blood-brain barrier penetration technologies to enhance drug delivery efficiency to the CNS.
  • The overview encompasses the current market status of technologies designed to penetrate the blood-brain barrier, providing details on various parameters. These include the development status (commercialized and under development), underlying technology principles (methods for drug delivery, biological approaches, physical techniques, etc.), types of pharmacological molecules compatible with blood-brain barrier penetration (biologics, small molecules, oligonucleotides, etc.), targeted disease indications, patent types, and licensing activities. The overview also profiles technology developers, detailing their establishment year, company size (in terms of workforce), and geographical location.
  • Detailed overview of the current market landscape of blood-brain barrier penetrating therapies that are approved or currently being evaluated in clinical trials, featuring a detailed analysis based on relevant parameters, such as stage of development (approved, phase III, phase II, phase I, IND-enabling, pre-clinical and discovery), type of molecule (biologics, small molecules and other molecules), affiliated BBB penetration, route of administration (intranasal, intravenous, oral, subcutaneous and transmucosal) target disease indication and therapeutic area (neurodegenerative disorders, lysosomal storage disorders, neuro oncology disorders, oncological disorders, infectious diseases, pain disorders, autoimmune disorders, CNS disorders, cerebrovascular disorders and others). Additionally, the chapter includes an overview on the landscape of BBB penetrating therapy developers, presenting a detailed analysis based on several relevant parameters, such as year of establishment, company size (based on employee count), location of headquarters and most active players (in terms of the number of therapies).
  • Comprehensive company profiles of prominent technology developers (shortlisted based on the following criteria: companies having more than three drugs (being developed using proprietary BBB technologies) in preclinical / clinical phase of development) in this domain, featuring an overview of the company, technology portfolio, product portfolio and recent developments and future outlook.
  • A detailed analysis of company competitiveness in the field of blood-brain barrier technologies is conducted based on key parameters. These include developer attributes such as experience duration, company size, and development status. Additionally, the analysis assesses technology strengths, focusing on factors like the types of pharmacological molecules compatible with blood-brain barrier penetration, availability of patent protection, number of collaborations, number of drugs developed, and the highest phase of development achieved.
  • This section provides a broad overview of the operational principles underlying prevalent approaches in the development of technologies aimed at penetrating the blood-brain barrier. These approaches include receptor-mediated transcytosis (RMT), which encompasses methods like bispecific antibodies and molecular trojan horse delivery via direct coupling or nanocarriers, strategies to enhance blood-brain barrier permeability, passive diffusion methods, and emerging techniques such as cell-penetrating peptides, macrocycles, and organ-on-a-chip technology.
  • An in-depth examination of partnerships within the blood-brain barrier industry is conducted, considering various parameters. These include the year of partnership establishment, partnership type, compatibility of pharmacological molecules, therapeutic area, partner type, and identification of the most active participants based on the number of partnerships formed. Additionally, the analysis covers the regional distribution of partnership activities occurring in this domain from the period prior to 2018 through March 2024.
  • This chapter provides a comprehensive exploration of the deal structures found in various types of technology licensing agreements within this field. It includes specifics on the rights pertaining to product ownership, associated royalties, upfront payments, and other contractual terms and conditions among industry stakeholders. The discussion is supported by detailed analysis based on key parameters such as the year of agreement, type of licensing agreement, the most active participants (in terms of the number of licensing agreements), the most popular technologies involved (in terms of the number of licensing agreements), and geographic considerations.
  • This analysis focuses on the funding and investments directed towards companies involved in the development of technologies and drugs for blood-brain barrier penetration. It encompasses various sources such as venture capital financing, funds raised through IPOs and subsequent offerings, grants, and debt financing. The detailed examination covers funding events occurring between 2020 and March 2024, emphasizing the increasing interest shown by the venture capital community and other strategic investors in this market.
  • This chapter provides a comprehensive analysis of patents filed or granted in the field of the blood-brain barrier since 2018. It examines several parameters including the year of patent publication, geographical distribution, CPC symbols, prominent players based on the number of patents filed or granted, and the type of organizations involved. Additionally, the chapter includes detailed patent benchmarking and valuation analysis, spotlighting leading patents based on the number of citations they have received.
  • A strategic analysis showcasing the predominant drug development strategies adopted by a majority of drug developers with clinical candidates in this field. The analysis aims to assist stakeholder companies in enhancing their current drug development approaches to expedite the advancement of their lead drug candidates.
  • A comprehensive 3D bubble chart illustrating the market potential of prevalent CNS disorders, prioritized by the number of blood-brain barrier (BBB) penetrant drugs in development. The chart considers metrics such as approved drugs, pipeline drugs, and the target patient population. It also features an in-depth discussion on epidemiological insights, causes, symptoms, ongoing development of BBB penetrant drugs for each specific disease, existing treatment options, and details of drugs already available on the market for each respective indication.
  • A compilation of over 240 drug developers focusing on Alzheimer’s disease and Parkinson’s disease, identified as potential partners for providers of blood-brain barrier penetration technologies. These developers have been selected based on criteria including their organizational strength (such as company size and years of experience in the field), the robustness and maturity of their pipelines (in terms of the number of drugs and their developmental stages), targeted indications, types of molecules used, routes of administration, and mechanisms of action.
  • Detailed analysis of the factors that can affect the growth of blood-brain barrier market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
  • Comprehensive market forecast analysis to estimate the existing market size and future opportunity for global blood-brain barrier penetrating therapies market over the next decade. Based on multiple parameters, such as likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period 2024-2035. The report also features the likely distribution of the current and forecasted opportunity within the global blood-brain barrier penetrating therapies market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
  • Comprehensive projections of the current and future blood-brain barrier penetrating therapies market across different types of molecules, such as small molecules and biologics.
  • Comprehensive projections of the current and future blood-brain barrier penetrating therapies market across various routes of administration, such as oral and intravenous.
  • Detailed projections of the current and future blood-brain barrier penetrating therapies market across different target disease indications, such as multiple sclerosis, mucopolysaccharidosis type II (hunter syndrome), amyotrophic lateral sclerosis, leptomeningeal carcinomatosis and mucopolysaccharidosis type III A (sanfilippo syndrome A).
  • Detailed projections of the current and future blood-brain barrier penetrating therapies market across various therapeutic areas, such as neurodegenerative disorders, lysosomal storage disorders and neuro-oncology disorders.
  • Detailed projections of the current and future blood-brain barrier penetrating therapies market across various key geographical regions, such as North America, Europe and Asia-Pacific and Rest of the World.
  • Details pertaining to the sales forecast for approved / phase III drugs in the BBB penetrating therapies market.

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the Blood Brain Barrier Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Excel Data Packs (Complimentary)

  • Blood-Brain Barrier Drugs Market Landscape
  • Blood-Brain Barrier Technology Market Landscape
  • Technology Competitiveness Analysis
  • Partnerships and Collaborations 
  • Recent Licensing Agreements Analysis
  • Funding and Investment Analysis 
  • Patent Analysis
  • Chessboard Strategy Analysis
  • Likely Partner Analysis
  • Market Size and Opportunity Analysis

Leading Market Companies

  • ICBI
  • Denali Therapeutics
  • JCR Pharmaceuticals
  • Cyclenium Pharma
  • Lauren Sciences
  • biOasis Technologies
  • Ossianix
  • Angiochem
  • Genervon Biopharmaceuticals
  • NEUWAY Pharma
  • Tranquis Therapeutics
  • CERES BRAIN Therapeutics
  • Nanomerics
  • Reglagene

Table of Contents

1. PREFACE
1.1 Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates
3.2.2. Currency Coverage and Foreign Exchange Rates
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
3.2.2.4. Strategies for Mitigating Foreign Exchange Risk
3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY
4.1. Chapter Overview

5. INTRODUCTION
5.1. Chapter Overview
5.2. Structure of the Human Brain
5.3. Growing Burden of Neurological Disorders
5.4. Strategies for Drug Delivery to the CNS
5.4.1. Invasive Techniques
5.4.1.1. Systemic Administration of Therapeutics
5.4.1.2. Direct Administration of Therapeutics
5.4.1.3. Intracerebral Devices and Implants
5.4.2. Non-Invasive Techniques / Approaches
5.4.2.1. Liposomes
5.4.2.2. Exosomes
5.4.2.3. Prodrugs
5.4.2.4. Nanoparticles and Microspheres
5.4.2.5. Novel Formulations and Conjugates
5.4.3. Chemical Delivery Systems
5.5. Blood-Brain Barrier
5.5.1. Key Historical Milestones
5.5.2. Structure and Key Components
5.5.3. Key Functions
5.6. Strategies for Drug Delivery Across the Blood-Brain Barrier
5.6.1. Increasing Permeability by Temporary Disruption of the Blood-Brain Barrier
5.6.2. Pharmacological Strategies to Facilitate Transport Across the Blood-Brain Barrier
5.7. Challenges Associated with BBB Penetration and CNS Drug Delivery
5.8. Concluding Remarks

6. MARKET LANDSCAPE: NON-INVASIVE BLOOD BRAIN BARRIER PENETRATION TECHNOLOGIES
6.1. Chapter Overview
6.2. Non-Invasive Blood-Brain Barrier Penetration Technologies: Overall Market Landscape
6.2.1. Analysis by Status of Development
6.2.2. Analysis by Technology Principle
6.2.3. Analysis by Compatible Pharmacological Molecule
6.2.4. Analysis by Type of Patent
6.2.5. Analysis by Licensing Activity
6.3. Non-Invasive Blood-Brain Barrier Penetration Technology Providers: Overall Market Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters

7. MARKET LANDSCAPE: BLOOD-BRAIN BARRIER PENETRATING THERAPIES
7.1. Chapter Overview
7.2. Blood-Brain Barrier Penetrating Therapies: Overall Market Landscape
7.2.1. Analysis by Stage of Development
7.2.2. Analysis by Type of Molecule
7.2.3. Analysis by Affiliated Blood-Brain Barrier Penetration Technology
7.2.4. Analysis by Route of Administration
7.2.5. Analysis by Target Disease Indication
7.2.6. Analysis by Therapeutic Area
7.3. Blood-Brain Barrier Penetrating Therapy Developers: Overall Market Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Most Active Developers: Analysis by Number of Therapies

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Companies based in North America
8.2.1. Angiochem
8.2.1.1. Company Overview
8.2.1.2. Technology Overview
8.2.1.3. Product Portfolio
8.2.1.4. Recent Developments and Future Outlook
8.2.2. biOasis Technologies
8.2.2.1. Company Overview
8.2.2.2. Technology Overview
8.2.2.3. Product Portfolio
8.2.2.4. Recent Developments and Future Outlook
8.2.3. Denali Therapeutics
8.2.3.1. Company Overview
8.2.3.2. Technology Overview
8.2.3.3. Product Portfolio
8.2.3.4. Recent Developments and Future Outlook
8.2.4. ICB International
8.2.4.1. Company Overview
8.2.4.2. Technology Overview
8.2.4.3. Product Portfolio
8.2.4.4. Recent Developments and Future Outlook
8.2.5. Lauren Sciences
8.2.5.1. Company Overview
8.2.5.2. Technology Overview
8.2.5.3. Product Portfolio
8.2.5.4. Recent Developments and Future Outlook
8.3. Companies based in Europe
8.3.1. Cyclenium Pharma
8.3.1.1. Company Overview
8.3.1.2. Technology Overview
8.3.1.3. Product Portfolio
8.3.1.4. Recent Developments and Future Outlook
8.3.2. NEUWAY Pharma
8.3.2.1. Company Overview
8.3.2.2. Technology Overview
8.3.2.3. Product Portfolio
8.3.2.4. Recent Developments and Future Outlook
8.3.3. Ossianix
8.3.3.1. Company Overview
8.3.3.2. Technology Overview
8.3.3.3. Product Portfolio
8.3.3.4. Recent Developments and Future Outlook
8.4. Companies based in Asia-pacific
8.4.1. JCR Pharmaceuticals
8.4.1.1. Company Overview
8.4.1.2. Technology Overview
8.4.1.3. Product Portfolio
8.4.1.4. Recent Developments and Future Outlook

9. TECHNOLOGY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Assumptions And Key Parameters
9.3. Methodology
9.4. Non-Invasive Blood-Brain Barrier Penetration Technologies: Competitiveness Analysis
9.4.1.1. Non-Invasive Blood-Brain Barrier Penetration Technologies Developed by Players based in North America
9.4.1.2. Non-Invasive BBB Penetration Technologies Developed by Players based in Europe and Asia-Pacific

10. NON-INVASIVE BBB PENETRATION TECHNOLOGIES: POPULAR APPROACHES
10.1. Chapter overview
10.2. Receptor Mediated Transcytosis (RMT)
10.2.1. Types of Target Receptors
10.2.1.1. Diphtheria Toxin Receptor
10.2.1.2. Insulin Receptor and Insulin-Like Growth Factor Receptor
10.2.1.3. Low Density Lipoprotein Receptor-Related Proteins (LRP 1 and LRP 2)
10.2.1.4. Transferrin Receptor
10.2.2. Types of RMT Approaches
10.2.2.1. Bispecific Antibody-based Approach
10.2.2.2. Molecular Trojan Horse-based Approach
10.2.2.2.1. Important Considerations for Designing Molecular Trojan Horses
10.2.2.2.2. Considerations for Designing a Trojan Horse Liposome (THL)
10.2.2.2.3. Popular Conjugation Strategies
10.2.2.2.3.1. Direct Coupling Approach
10.2.2.2.3.2. Nanoparticles-based Approach
10.3. Increasing the Permeability of the BBB
10.3.1. Use of Ultrasound Waves
10.3.2. Use of High-Frequency Electric Field
10.4. Passive Diffusion
10.5. Novel Approaches
10.5.1. Cell Penetrating Peptides
10.5.2. Macrocycles
10.5.3. Organ-on-A-Chip Technology

11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. Non-Invasive BBB Technologies and Drugs: Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Year and Type of Partnership
11.3.4. Analysis by Type of Partner
11.3.5. Analysis by Focus Area of Partnership
11.3.6. Analysis by Type of Molecule
11.3.7. Most Active Players: Analysis by Number of Partnerships
11.3.8. Analysis by Geography
11.3.8.1. Local and International Agreements
11.3.8.2. Intercontinental and Intracontinental Agreements

12. RECENT LICENSING AGREEMENTS ANALYSIS
12.1. Chapter Overview
12.2. Licensing Agreements: Importance in Pharmaceutical Industry
12.3. Types of Licensing Agreements
12.3.1. Out-Licensing Agreements
12.3.2. In-Licensing Agreements
12.4. Components of Licensing Agreements
12.5. Recent Examples of BBB Related Technology and Therapy Licensing Agreements
12.5.1. Analysis by Year of Agreement
12.5.2. Analysis by Type of Licensing Agreement
12.5.3. Most Active Players: Analysis by Number of Licensing Agreements
12.5.4. Most Popular Technologies: Analysis by Number of Licensing Agreements
12.5.5. Analysis by Geography
12.5.5.1. Local and International Licensing Agreements
12.5.5.2. Intercontinental and Intracontinental Licensing Agreements

13. FUNDING AND INVESTMENT ANALYSIS
13.1. Chapter Overview
13.2. Types of Funding
13.3. Non-Invasive BBB Penetration Drugs and Technologies: Funding and Investments
13.3.1. Analysis by Year of Investment
13.3.2. Analysis by Amount Invested
13.3.3. Analysis by Type of Funding
13.3.4. Analysis of Amount Invested by Type of Funding
13.3.5. Analysis by Year of Investment and Type of Funding
13.3.6. Analysis By Type of Compatible Pharmacological Molecule
13.3.7. Most Active players: Analysis by Number of Instances
13.3.8. Most Active Players: Analysis by Amount Raised
13.3.9. Most Active Investors: Analysis by Number of Instances
13.3.10. Analysis by Geography

14. PATENT ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Blood-Brain Barrier Penetration Technologies and Drugs: Patent Analysis
14.3.1. Analysis by Patent Application Year
14.3.2. Analysis by Patent Publication Year
14.3.3. Analysis of Granted Patents and Patent Applications by Publication Year
14.3.4. Analysis by Patent Jurisdiction
14.3.5. Analysis by CPC Symbols
14.3.6. Analysis by Type of Applicant
14.3.7. Leading Industry Players: Analysis by Number of Patents
14.3.8. Leading Non-Industry Players: Analysis by Number of Patents
14.3.9. Leading Patent Assignees: Analysis by Number of Patents
14.4. Patent Benchmarking Analysis
14.4.1. Analysis By Patent Characteristics
14.5. Patent Valuation
14.5.1. Leading Patents by Number of Citations

15. DRUG DEVELOPMENT: CHESSBOARD STRATEGY ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Strategy Adopted for Late-Stage Drug Candidates
15.3.1. IZCARGO / JR-141 / Pabinafusp Alfa (JCR Pharmaceuticals)
15.3.2. UX-111 / ABO-102 (Ultragenyx)
15.3.3. ANG1005 / Paclitaxel Trevatide (Angiochem)
15.3.4. ANX005 (Annexon Biosciences)
15.3.5. SAR-442168 / PRN2246 (Sanofi)
15.4. Concluding Remarks

16. MARKET POTENTIAL FOR KEY NEUROLOGICAL DISORDERS
16.1. Chapter Overview
16.2. Market Potential for Key Neurological Disorders
16.3. Methodology and Key Parameters
16.4. Key Neurological Disorders
16.4.1. Alzheimer’s Disease
16.4.1.1. Epidemiology
16.4.1.2. Symptoms
16.4.1.3. Current Treatment Options
16.4.1.3.1. Interventional Therapies
16.4.1.3.2. Non-Interventional Therapies
16.4.1.4. BBB Penetrating Drugs for Alzheimer’s Disease
16.4.1.5. Market Potential for Alzheimer’s disease
16.4.2. Brain Cancer
16.4.2.1. Epidemiology
16.4.2.2. Symptoms
16.4.2.3. Current Treatment Options
16.4.2.3.1. Surgery
16.4.2.3.2. Radiation Therapy
16.4.2.3.3. Systemic Therapy
16.4.2.4. BBB Penetrating Drugs for Brain Cancer
16.4.2.5. Market Potential for Brain Cancer
16.4.3. Multiple Sclerosis
16.4.3.1. Epidemiology
16.4.3.2. Symptoms
16.4.3.3. Current Treatment Options
16.4.3.3.1. Treatment for Attacks
16.4.3.3.2. Treatments to Modify Progression
16.4.3.3.3. Interferons
16.4.3.4. BBB Penetrating Drugs for Multiple Sclerosis
16.4.3.5. Market Potential for Multiple Sclerosis
16.4.4. Parkinson’s Disease
16.4.4.1. Epidemiology
16.4.4.2. Symptoms
16.4.4.3. Current Treatment Options
16.4.4.3.1. Pharmacological Management of Parkinson’s Disease
16.4.4.3.2. Non-Pharmacological Management of Parkinson’s Disease
16.4.4.3.3. Management of Parkinson’s Disease Using Dietary Supplements
16.4.4.4. BBB Penetrating Drugs for Parkinson’s Disease
16.4.4.5. Market Potential for Parkinson’s Disease

17. LIKELY PARTNER ANALYSIS
17.1. Chapter Overview
17.2. Scoring Criteria and Key Assumptions
17.3. Scope and Methodology
17.4. Potential Strategic Partners for Blood-Brain Barrier Technology Providers
17.4.1. Likely Partners in North America
17.4.2. Likely Partners in Europe
17.4.3. Likely Partners in Asia-Pacific and Rest of the World

18. MARKET IMPACT ANALYSIS
18.1. Chapter Overview
18.2. Market Drivers
18.3. Market Restraints
18.4. Market Opportunities
18.5. Market Challenges
18.6. Conclusion

19. GLOBAL BLOOD-BRAIN BARRIER PENETRATING THERAPIES MARKET
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Global Blood-Brain Barrier Penetrating Therapies Market, 2024-2035
19.3.1. Scenario Analysis
19.3.1.1. Conservative Scenario
19.3.1.2. Optimistic Scenario
19.4. Key Market Segmentations

20. BLOOD-BRAIN BARRIER PENETRATING THERAPIES MARKET, BY TYPE OF MOLECULE
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Blood-Brain Barrier Penetrating Therapies Market: Distribution by Type of Molecule, 2024, 2029 and 2035
20.3.1. Blood-Brain Barrier Penetrating Therapies Market for Biologics: Forecasted Estimates (2024-2035)
20.3.2. Blood-Brain Barrier Penetrating Therapies Market for Small Molecule: Forecasted Estimates (2026-2035)
20.3. Data Triangulation and Validation

21. BLOOD-BRAIN BARRIER PENETRATING THERAPIES MARKET, BY ROUTE OF ADMINISTRATION
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Blood-Brain Barrier Penetrating Therapies Market: Distribution by Route of Administration, 2024 and 2035
21.3.1. Blood-Brain Barrier Penetrating Therapies Market for Intravenous Route of Administration: Forecasted Estimates (2024-2035)
21.3.2. Blood-Brain Barrier Penetrating Therapies Market for Oral Route of Administration: Forecasted Estimates (2026-2035)
21.4. Data Triangulation and Validation

22. BLOOD-BRAIN BARRIER PENETRATING THERAPIES MARKET, BY TARGET DISEASE INDICATION
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Blood-Brain Barrier Penetrating Therapies Market: Distribution by Target Indication, 2024, 2029 and 2035
22.3.1. Blood-Brain Barrier Penetrating Therapies Market for Mucopolysaccharidosis Type II (Hunter Syndrome): Forecast Estimates (2024-2035)
22.3.2. Blood-Brain Barrier Penetrating Therapies Market for Multiple Sclerosis: Forecast Estimates (2026-2035)
22.3.3. Blood-Brain Barrier Penetrating Therapies Market for Amyotrophic Lateral Sclerosis: Forecast Estimates (2028-2035)
22.3.4. Blood-Brain Barrier Penetrating Therapies Market for Leptomeningeal Carcinomatosis: Forecast Estimates (2026-2035)
22.3.5. Blood-Brain Barrier Penetrating Therapies Market for Mucopolysaccharidosis Type III A (Sanfilippo Syndrome A): Forecast Estimates (2028-2035)
22.4. Data Triangulation and Validation

23. BLOOD-BRAIN BARRIER PENETRATING THERAPIES MARKET, BY THERAPEUTIC AREA
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Blood-Brain Barrier Penetrating Therapies Market: Distribution by Therapeutic Area, 2024, 2029 and 2035
23.3.1. Blood-Brain Barrier Penetrating Therapies Market for Lysosomal Storage Disorders: Forecast Estimates (2024-2035)
23.3.2. Blood-Brain Barrier Penetrating Therapies Market for Neurodegenerative Disorders: Forecast Estimates (2026-2035)
23.3.3. Blood-Brain Barrier Penetrating Therapies Market for Neuro-Oncology Disorders: Forecast Estimates (2026-2035)
23.4. Data Triangulation and Validation

24. BLOOD-BRAIN BARRIER PENETRATING THERAPIES MARKET, BY KEY GEOGRAPHICAL REGIONS
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Blood-Brain Barrier Penetrating Therapies Market: Distribution by Key Geographical Regions, 2024, 2029 and 2035
24.3.1. Blood-Brain Barrier Penetrating Therapies Market in North America: Forecasted Estimates (2026-2035)
24.3.2. Blood-Brain Barrier Penetrating Therapies Market in Europe: Forecasted Estimates (2028-2035)
24.3.3. Blood-Brain Barrier Penetrating Therapies Market in Asia-Pacific and Rest of the World: Forecasted Estimates (2024-2035)
24.4. Data Triangulation and Validation

25. BLOOD-BRAIN BARRIER PENETRATING THERAPIES MARKET, SALES FORECAST OF DRUGS
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Commercialized Blood-Brain Barrier Penetrating Therapies: Sales Forecast
25.3.1. Izcargo / JR-141 / Pabinafusp Alfa Sales Forecast
25.4. Phase III Blood-Brain Barrier Penetrating Therapies: Sales Forecast
25.4.1. ANG1005 / Paclitaxel Trevatide / GRN1005 Sales Forecast
25.4.2. SAR-442168 / PRN2246 Sales Forecast
25.4.3. UX-111 / ABO-102 Sales Forecast
25.5. Phase II/III Blood-Brain Barrier Penetrating Therapies: Sales Forecast
25.5.1. DNL310 / ETV:IDS Sales Forecast
25.5.2. DNL343 Sales Forecast

26. CONCLUSION
27. EXECUTIVE INSIGHTS
27.1. Chapter Overview
27.2. Innovative California Biosciences International (ICBI)
27.2.1. Company Snapshot
27.2.2. Interview Transcript: Ram Bhatt, Chief Executive Officer, Chairman and Founder
27.3. Ossianix
27.3.1. Company Snapshot
27.3.2. Interview Transcript: Frank S Walsh, Chief Executive Officer and Founder
27.4. 2-BBB
27.4.1. Company Snapshot
27.4.2. Interview Transcript: Pieter Gaillard, Chief Executive Officer and Co-Founder
27.5. ArmaGen
27.5.1. Company Snapshot
27.5.2. Interview Transcript: Mathias Schmidt, Chief Executive Officer
27.6. biOasis Technologies
27.6.1. Company Snapshot
27.6.2. Interview Transcript: Rob Hutchison, Chief Executive Officer
27.7. Cyclenium Pharma
27.7.1. Company Snapshot
27.7.2. Interview Transcript: Mark L Peterson, Chief Operating Officer
27.8. Sagetis Biotech
27.8.1. Company Snapshot
27.8.2. Interview Transcript: Xavier Rivero, Chief Operating Officer
27.9. CarThera
27.9.1. Company Snapshot
27.9.2. Interview Transcript: Carole Desseaux, Head of Clinical Affairs
27.10. Vect-Horus
27.10.1. Company Snapshot
27.10.2. Interview Transcript: Jamal Temsamani, Head of Drug Development
27.11. Wyss Institute, Harvard University
27.11.1. Organization Snapshot
27.11.2. Interview Transcript: Kevin Kit Parker, Professor

28. APPENDIX I: TABULATED DATA29. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentations
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Non-Invasive Blood-Brain Barrier Technologies Market Landscape
Figure 4.2 Executive Summary: Blood-Brain Barrier Penetrating Therapies Market Landscape Market Landscape
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Patent Analysis
Figure 4.5 Executive Summary: Funding and Investment Analysis
Figure 4.6 Executive Summary: Market Sizing and Opportunity Analysis
Figure 5.1 Structure of the Human Brain
Figure 5.2 Types of Neurological Disorders
Figure 5.3 Strategies for Drug Delivery to CNS
Figure 5.4 Key Historical Milestones in Blood-Brain Barrier Research
Figure 5.5 Pathway Associated with the Blood-Brain Barrier
Figure 5.6 Transport Systems Associated with the Blood-Brain Barrier
Figure 6.1 Non-Invasive Blood-Brain Barrier Penetration Technologies: Distribution by Status of Development
Figure 6.2 Non-Invasive Blood-Brain Barrier Penetration Technologies: Distribution by Technology Principle
Figure 6.3 Non-Invasive Blood-Brain Barrier Penetration Technologies: Distribution by Compatible Pharmacological Molecule
Figure 6.4 Non-Invasive Blood-Brain Barrier Penetration Technologies: Distribution by Type of Patent
Figure 6.5 Non-Invasive Blood-Brain Barrier Penetration Technologies: Distribution by Licensing Activity
Figure 6.6 Non-Invasive Blood-Brain Barrier Technology Providers: Distribution by Year of Establishment
Figure 6.7 Non-Invasive Blood-Brain Barrier Technology Developers: Distribution by Company Size
Figure 6.8 Non-Invasive Blood-Brain Barrier Technology Providers: Distribution by Location of Headquarters (Region)
Figure 7.1 Blood-Brain Barrier Penetrating Therapies: Distribution by Stage of Development
Figure 7.2 Blood-Brain Barrier Penetrating Therapies: Distribution by Type of Molecule
Figure 7.3 Blood-Brain Barrier Penetrating Therapies: Distribution by Affiliated Blood-Brain Barrier Penetration Technology
Figure 7.4 Blood-Brain Barrier Penetrating Therapies: Distribution by Route of Administration
Figure 7.5 Blood-Brain Barrier Penetrating Therapies: Distribution by Target Disease Indication
Figure 7.6 Blood-Brain Barrier Penetrating Therapies: Distribution by Therapeutic Area
Figure 7.7 Blood-Brain Barrier Penetrating Therapy Developers: Distribution by Year of Establishment
Figure 7.8 Blood-Brain Barrier Penetrating Therapy Developers: Distribution by Company Size
Figure 7.9 Blood-Brain Barrier Penetrating Therapy Developers: Distribution by Location of Headquarters
Figure 7.10 Most Active Developers: Distribution by Number of Therapies
Figure 9.1 Competitiveness Analysis: Non-Invasive Blood-Brain Barrier Penetration Technologies Developed by Players based in North America
Figure 9.2 Competitiveness Analysis: Non-Invasive Blood-Brain Barrier Penetration Technologies Developed by Players based in Europe and Asia-Pacific
Figure 10.1 Receptor Mediated Transcytosis: Key Functions
Figure 10.2 Receptor Mediated Transcytosis: Working Mechanism
Figure 10.3 Trojan Horse-based Approach: Working Mechanism
Figure 11.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2018-2024
Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Pre-2018-2024
Figure 11.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 11.5 Partnerships and Collaborations: Distribution by Focus Area of Partnership
Figure 11.6 Partnerships and Collaborations: Distribution by Type of Molecule
Figure 11.7 Most Active Players: Distribution by Number of Partnerships
Figure 11.8 Partnerships and Collaboration: Local and International Agreements
Figure 11.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 12.1 Key Risks and Benefits Associated with a Licensee
Figure 12.2 Key Risks and Benefits Associated with a Licensor
Figure 12.3 Licensing Agreements: Distribution of Financial Components
Figure 12.4 Recent Licensing Agreements: Cumulative Year-Wise Trend, Pre-2020-2024
Figure 12.5 Recent Licensing Agreements: Distribution by Type of Agreement
Figure 12.6 Most Active Players: Distribution by Number of Licensing Agreements
Figure 12.7 Most Popular Technologies: Distribution by Number of Licensing Agreements
Figure 12.8 Recent Licensing Agreements: Local and International Agreements
Figure 12.9 Recent Licensing Agreements: Intercontinental and Intracontinental Agreements
Figure 13.1 Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, 2020 - 2024
Figure 13.2 Funding and Investment Analysis: Cumulative Year-wise Distribution by Amount Invested, 2020-2024 (USD Million)
Figure 13.3 Funding and Investment Analysis: Distribution by Type of Funding
Figure 13.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding
Figure 13.5 Funding and Investment Analysis: Distribution by Year of Investment and Type of Funding, 2020-2024
Figure 13.6 Funding and Investment Analysis: Distribution by Type of Compatible Pharmacological Molecule
Figure 13.7 Most Active Players: Distribution by Number of Instances
Figure 13.8 Most Active Players: Distribution by Amount Raised (USD Million))
Figure 13.9 Most Active Investors: Distribution by Number of Instances
Figure 13.10 Funding and Investment Analysis: Distribution by Geography (Region)
Figure 13.11 Funding and Investment Analysis: Distribution by Geography (Country)
Figure 14.1 Patent Analysis: Distribution by Type of Patent
Figure 14.2 Patent Analysis: Cumulative Year-wise Trend by Patent Application Year, Pre-2015-2023
Figure 14.3 Patent Analysis: Cumulative Year-wise Trend by Patent Publication Year, 2019-2024
Figure 14.4 Patent Analysis: Distribution by Type of Patent and Patent Publication Year, 2019-2024
Figure 14.5 Patent Analysis: Distribution by Patent Jurisdiction (Region)
Figure 14.6 Patent Analysis: Distribution by Patent Jurisdiction (Country)
Figure 14.7 Patent Analysis: Distribution by CPC Symbols
Figure 14.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2019-2024
Figure 14.9 Leading Industry Players: Distribution by Number of Patents
Figure 14.10 Leading Non-Industry Players: Distribution by Number of Patents
Figure 14.11 Leading Patent Assignees: Distribution by Number of Patents
Figure 14.12 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Players
Figure 14.13 Patent Benchmarking Analysis: Distribution of Leading Players by Patent Characteristics (Top CPC Codes)
Figure 14.14 Patent Analysis: Distribution by Patent Age
Figure 14.15 BBB Penetration Technologies and Drugs Domain: Patent Valuation
Figure 15.1 Strategies Adopted for Late-Stage Drug Candidates
Figure 15.2 Drug Development Strategies: IZCARGO / JR-141 / Pabinafusp Alfa
Figure 15.3 Drug Development Strategies: UX-111 / ABO-102
Figure 15.4 Drug Development Strategies: ANG1005 / Paclitaxel Trevatide
Figure 15.5 Drug Development Strategies: ANX005
Figure 15.6 Drug Development Strategies: SAR-442168 / PRN2246
Figure 15.7 BBB Penetrating Drug Developers: Popular Development Strategies
Figure 15.8 Drug Development Strategy: Preferred Paths to Market
Figure 16.1 Market Potential for Key Neurological Disorders: 3D Bubble Analysis Based on Number of Approved Drugs, Strength of Pipeline and Target Patient Population
Figure 16.2 Normal Brain versus Diseased Brain
Figure 16.3 Alzheimer’s Disease: Phases of Disease Progression
Figure 16.4 Global Statistics of Dementia: 2015 and 2030 (in Millions)
Figure 16.5 Alzheimer’s Disease: Signs and Symptoms
Figure 16.6 Dietary Supplements for Disease Management
Figure 16.7 Market Potential for Alzheimer’s Disease: 3D Bubble Analysis Based on Number of Approved Drugs, Strength of Pipeline and Target Patient Population
Figure 16.8 Brain Cancer: Signs and Symptoms
Figure 16.9 Market Potential for Brain Cancer: 3D Bubble Analysis Based on Number of Approved Drugs, Strength of Pipeline and Target Patient Population
Figure 16.10 Multiple Sclerosis: Signs and Symptoms
Figure 16.11 Market Potential for Multiple Sclerosis: 3D Bubble Analysis Based on Number of Approved Drugs, Strength of Pipeline and Target Patient Population
Figure 16.12 Parkinson’s Disease: Causal Environmental Factors
Figure 16.13 Parkinson’s Disease: Gender-wise Incidence Rates
Figure 16.14 Parkinson’s Disease: Disease Stages
Figure 16.15 Parkinson’s Disease: Motor Symptoms
Figure 16.16 Parkinson’s Disease: Secondary Symptoms
Figure 16.17 Parkinson’s Disease Management: Non-Pharmacological Treatment Options
Figure 16.18 Parkinson’s Disease Management: Surgical Methods
Figure 16.19 Parkinson’s Disease Management: Dietary Supplements
Figure 16.20 Market Potential for Parkinson’s Disease: 3D Bubble Analysis Based on Number of Approved Drugs, Strength of Pipeline and Target Patient Population
Figure 19.1 Global Blood-Brain Barrier Penetrating Therapies Market, 2024-2035 (USD Million)
Figure 19.2 Global Blood-Brain Barrier Penetrating Therapies Market, 2024-2035: Conservative Scenario (USD Million)
Figure 19.3 Global Blood-Brain Barrier Penetrating Therapies Market, 2024-2035: Optimistic Scenario (USD Million)
Figure 20.1 Blood-Brain Barrier Penetrating Therapies Market: Distribution by Type of Molecule, 2024, 2029 and 2035
Figure 20.2 Blood-Brain Barrier Penetrating Therapies Market for Biologics: Forecasted Estimates (2025-2035) (USD Million)
Figure 20.3 Blood-Brain Barrier Penetrating Therapies Market for Small Molecules: Forecasted Estimates (2026-2035) (USD Million)
Figure 21.1 Blood-Brain Barrier Penetrating Therapies Market: Distribution by Route of Administration, 2024, 2029 and 2035
Figure 21.2 Blood-Brain Barrier Penetrating Therapies Market for Intravenous Route of Administration: Forecasted Estimates (2024-2035) (USD Million)
Figure 21.3 Blood-Brain Barrier Penetrating Therapies Market for Oral Route of Administration: Forecasted Estimates (2024-2035) (USD Million)
Figure 22.1 Blood-Brain Barrier Penetrating Therapies Market: Distribution by Target Indication, 2024, 2029 and 2035
Figure 22.2 Blood-Brain Barrier Penetrating Therapies Market for Mucopolysaccharidosis Type II (Hunter Syndrome): Forecasted Estimates (2024-2035) (USD Million)
Figure 22.3 Blood-Brain Barrier Penetrating Therapies Market for Multiple Sclerosis: Forecasted Estimates (2026-2035) (USD Million)
Figure 22.4 Blood-Brain Barrier Penetrating Therapies Market for Amyotrophic Lateral Sclerosis: Forecasted Estimates (2028-2035) (USD Million)
Figure 22.5 Blood-Brain Barrier Penetrating Therapies Market for Leptomeningeal Carcinomatosis: Forecasted Estimates (2026-2035) (USD Million)
Figure 22.6 Blood-Brain Barrier Penetrating Therapies Market for Mucopolysaccharidosis Type III A (Sanfilippo Syndrome A): Forecasted Estimates (2028-2035) (USD Million)
Figure 23.1 Blood-Brain Barrier Penetrating Therapies Market: Distribution by Therapeutic Area, 2024, 2029 and 2035
Figure 23.2 Blood-Brain Barrier Penetrating Therapies Market for Lysosomal Storage Disorders: Forecasted Estimates (2024-2035) (USD Million)
Figure 23.3 Blood-Brain Barrier Penetrating Therapies Market for Neurodegenerative Disorders: Forecasted Estimates (2026-2035) (USD Million)
Figure 23.4 Blood-Brain Barrier Penetrating Therapies Market for Neuro-Oncology Disorders: Forecasted Estimates (2026-2035) (USD Million)
Figure 24.1 Blood-Brain Barrier Penetrating Therapies Market: Distribution by Key Geographical Regions, 2024 and 2035 (USD Million)
Figure 24.2 Blood-Brain Barrier Penetrating Therapies Market in North America: Forecasted Estimates (2026-2035) (USD Million)
Figure 24.3 Blood-Brain Barrier Penetrating Therapies Market in Europe: Forecasted Estimates (2028-2035) (USD Million)
Figure 24.4 Blood-Brain Barrier Penetrating Therapies Market in Asia-Pacific and RoW: Forecasted Estimates (2024-2035) (USD Million)
Figure 25.1 Blood-Brain Barrier Penetrating Therapies Market: Izcargo / JR-141 / Pabinafusp Alfa Sales Forecast, 2024-2035 (USD Million)
Figure 25.2 Blood-Brain Barrier Penetrating Therapies Market: ANG1005 / Paclitaxel Trevatide / GRN1005 Sales Forecast, 2026-2035 (USD Million)
Figure 25.3 Blood-Brain Barrier Penetrating Therapies Market: SAR-442168 / PRN2246 Sales Forecast, 2026-2035 (USD Million)
Figure 25.4 Blood-Brain Barrier Penetrating Therapies Market: UX-111 / ABO-102 Sales Forecast, 2028-2035 (USD Million)
Figure 25.5 Blood-Brain Barrier Penetrating Therapies Market: DNL310 / ETV: IDS Sales Forecast, 2026-2035 (USD Million)
Figure 25.6 Blood-Brain Barrier Penetrating Therapies Market: DNL343 Sales Forecast, 2028-2035 (USD Million)
Figure 26.1 Concluding Remarks: Blood-Brain Barrier Penetration Technologies Market Landscape
Figure 26.2 Concluding Remarks: Blood-Brain Barrier Penetration Therapies Market Landscape
Figure 26.3 Concluding Remarks: Partnerships and Collaborations
Figure 26.4 Concluding Remarks: Recent Licensing Agreements
Figure 26.5 Concluding Remarks: Funding and Investment Analysis
Figure 26.6 Concluding Remarks: Patents Analysis
Figure 26.7 Concluding Remarks: Market Sizing and Opportunity Analysis

LIST OF TABLES
Table 5.1 Key Components of the Human Brain
Table 5.2 Commercially Available Devices for Drug Delivery in CNS
Table 5.3 Key Differences: Non-Invasive and Invasive Blood-Brain Barrier Technologies
Table 5.4 List of Key Constituents of the Blood-Brain Barrier
Table 5.5 Key Functions of the Blood Brain Barrier
Table 5.6 List of Blood-Brain Transporters
Table 6.1 Non-Invasive Blood-Brain Barrier Penetration Technologies: List of Technology Platforms
Table 6.2 Invasive Blood-Brain Barrier Penetration Technologies: List of Technology Platforms
Table 6.3 Non-Invasive Blood-Brain Barrier Penetration Technologies: List of Technology Developers
Table 7.1 Blood-Brain Barrier Penetrating Therapies: Information on Developer, Stage of Development, Type of Molecule and Affiliated Blood-Brain Barrier Penetration Technology
Table 7.2 Blood-Brain Barrier Penetrating Therapies: Information on Route of Administration, Target Disease Indication and Therapeutic Area
Table 7.3 Blood-Brain Barrier Penetrating Therapy Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 8.1 Blood Brain Barrier: List of Companies Profiled
Table 8.2 Angiochem: Company Overview
Table 8.3 Angiochem: Product Portfolio
Table 8.4 biOasis Technologies: Company Overview
Table 8.5 biOasis Technologies: Product Portfolio
Table 8.6 biOasis Technologies: Recent Developments and Future Outlook
Table 8.7 Denali Therapeutics: Company Overview
Table 8.7 Denali Therapeutics: Product Portfolio
Table 8.9 Denali Therapeutics: Recent Developments and Future Outlook
Table 8.10 ICB International: Company Overview
Table 8.11 ICB International: Product Portfolio
Table 8.12 Lauren Sciences: Company Overview
Table 8.13 Lauren Sciences: Product Portfolio
Table 8.14 Cyclenium Pharma: Company Overview
Table 8.15 Cyclenium Pharma: Product Portfolio
Table 8.16 NEUWAY Pharma: Company Overview
Table 8.17 NEUWAY Pharma: Product Portfolio
Table 8.18 Ossianix: Company Overview
Table 8,19 Ossianix: Product Portfolio
Table 8.20 JCR Pharmaceuticals: Company Overview
Table 8.21 JCR Pharmaceuticals: Product Portfolio
Table 8.22 JCR Pharmaceuticals: Recent Developments and Future Outlook
Table 11.1 Non-Invasive Blood-Brain Barrier Penetration Technologies and Drugs: List of Partnerships and Collaborations, Pre-2018-2024
Table 12.2 Non-Invasive Blood-Brain Barrier Penetration Technologies: List of Recent Licensing Agreements, Pre-2020-2024
Table 13.1 Funding and Investment Analysis: List of Funding and Investments, 2020-2024
Table 14.1 Patent Analysis: Top CPC Sections
Table 14.2 Patent Analysis: Top CPC Symbols
Table 14.3 Patent Analysis: List of Top CPC Codes
Table 14.4 Patent Analysis: Summary of Benchmarking Analysis
Table 14.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 14.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 14.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 15.1 Drug Development Strategy: List of Blood-Brain Barrier Penetrating Therapies
Table 16.1 Alzheimer’s Disease: List of Marketed Drugs
Table 16.2 Blood-Brain Barrier Penetrating Drugs Pipeline for Alzheimer’s Disease
Table 16.3 Brain Cancer: List of Marketed Drugs
Table 16.4 Blood-Brain Barrier Penetrating Drugs Pipeline for Brain Cancer
Table 16.5 Multiple Sclerosis: List of Marketed Drugs
Table 16.6 Blood-Brain Barrier Penetrating Drugs Pipeline for Multiple Sclerosis
Table 16.7 Parkinson’s Disease: List of Marketed Drugs
Table 16.8 Blood-Brain Barrier Penetrating Drugs Pipeline for Parkinson’s Disease
Table 17.1 Likely Partners in North America
Table 17.2 Likely Partners in Europe
Table 17.3 Likely Partners in Asia-Pacific and Rest of the World
Table 19.1 List of Blood-Brain Barrier Penetrating Therapies Market Therapies Forecasted
Table 28.1 Non-Invasive Blood-Brain Barrier Penetration Technologies: Distribution by Status of Development
Table 28.2 Non-Invasive Blood-Brain Barrier Penetration Technologies: Distribution by Technology Principle
Table 28.3 Non-Invasive Blood-Brain Barrier Penetration Technologies: Distribution by Compatible Pharmacological Molecule
Table 28.4 Non-Invasive Blood-Brain Barrier Penetration Technologies: Distribution by Type of Patent
Table 28.5 Non-Invasive Blood-Brain Barrier Penetration Technologies: Distribution by Licensing Activity
Table 28.6 Non-Invasive BBB Technology Providers: Distribution by Year of Establishment
Table 28.7 Non-Invasive Blood-Brain Barrier Technology Providers: Distribution by Company Size
Table 28.8 Non-Invasive BBB Technology Providers: Distribution by Location of Headquarters
Table 28.9 Blood-Brain Barrier Penetrating Therapies: Distribution by Stage of Development
Table 28.10 Blood-Brain Barrier Penetrating Therapies: Distribution by Type of Molecule
Table 28.11 Blood-Brain Barrier Penetrating Therapies: Distribution by Affiliated Blood-Brain Barrier Penetration Technology
Table 28.12 Blood-Brain Barrier Penetrating Drugs: Distribution by Route of Administration
Table 28.13 Blood-Brain Barrier Penetrating Therapies: Distribution by Target Disease Indication
Table 28.14 Blood-Brain Barrier Penetrating Therapies: Distribution by Therapeutic Area
Table 28.15 Blood-Brain Barrier Penetrating Therapy Developers: Distribution by Year of Establishment
Table 28.16 Blood-Brain Barrier Penetrating Therapy Developers: Distribution by Company Size
Table 28.17 Blood-Brain Barrier Penetrating Therapy Developers: Distribution by Location of Headquarters
Table 28.18 Most Active Developers: Distribution by Number of Therapies
Table 28.19 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2018-2024
Table 28.20 Partnerships and Collaborations: Distribution by Type of Partnership
Table 28.21 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Pre-2018-2024
Table 28.22 Partnerships and Collaborations: Distribution by Type of Partner
Table 28.23 Partnerships and Collaborations: Distribution by Focus Area of Partnership
Table 28.24 Partnerships and Collaborations: Distribution by Type of Molecule
Table 28.25 Most Active Players: Distribution by Number of Partnerships
Table 28.26 Partnership and Collaborations: Local and International Agreements
Table 28.27 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 28.28 Recent Licensing Agreements: Cumulative Year-Wise Trend, Pre-2020-2024
Table 28.29 Recent Licensing Agreements: Distribution by Type of Agreement
Table 28.30 Most Active Players: Distribution by Number of Licensing Agreements
Table 28.31 Most Popular Technologies: Distribution by Number of Licensing Agreements
Table 28.32 Recent Licensing Agreements: Local and International Agreements
Table 28.33 Recent Licensing Agreements: Intercontinental and Intracontinental Agreements
Table 28.34 Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, 2020 - 2024
Table 28.35 Funding and Investment Analysis: Cumulative Year-wise Distribution by Amount Invested, 2020-2024 (USD Million)
Table 28.36 Funding and Investment Analysis: Distribution by Type of Funding
Table 28.37 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding
Table 28.38 Funding and Investment Analysis: Distribution by Type of Compatible Pharmacological Molecule
Table 28.39 Most Active Players: Distribution by Number of Instances
Table 28.40 Most Active Players: Distribution by Amount Raised (USD Million)
Table 28.41 Most Active Investors: Distribution by Number of Instances
Table 28.42 Funding and Investment Analysis: Distribution by Geography (Region)
Table 28.43 Funding and Investment Analysis: Distribution by Geography (Country)
Table 28.44 Patent Analysis: Distribution by Type of Patent
Table 28.45 Patent Analysis: Cumulative Year-wise Trend by Patent Application Year, Pre-2015-2023
Table 28.46 Patent Analysis: Cumulative Year-wise Trend by Patent Application Year, Pre-2015-2023
Table 28.47 Patent Analysis: Distribution by Type of Patent and Patent Publication Year, 2019-2024
Table 28.48 Patent Analysis: Distribution by Patent Jurisdiction (Region)
Table 28.49 Patent Analysis: Distribution by Patent Jurisdiction (Country)
Table 28.50 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 28.51 Leading Industry Players: Distribution by Number of Patents
Table 28.52 Leading Non-Industry Players: Distribution by Number of Patents
Table 28.53 Leading Patent Assignees: Distribution by Number of Patents
Table 28.54 Patent Analysis: Distribution by Patent Age
Table 28.55 Global Blood-Brain Barrier Penetrating Therapies Market, 2024-2035 (USD Million)
Figure 28.56 Global Blood-Brain Barrier Penetrating Therapies Market, 2024-2035 (USD Million)
Figure 28.57 Global Blood-Brain Barrier Penetrating Therapies Market, 2024-2035: Conservative Scenario (USD Million)
Figure 28.58 Global Blood-Brain Barrier Penetrating Therapies Market, 2024-2035: Optimistic Scenario (USD Million)
Figure 28.59 Blood-Brain Barrier Penetrating Therapies Market: Distribution by Type of Molecule, 2024, 2029 and 2035
Table 28.60 Blood-Brain Barrier Penetrating Therapies Market for Biologics: Forecasted Estimates (2025-2035) (USD Million)
Table 28.61 Blood-Brain Barrier Penetrating Therapies Market for Small Molecules: Forecasted Estimates (2026-2035) (USD Million)
Table 28.62 Blood-Brain Barrier Penetrating Therapies Market: Distribution by Route of Administration, 2024, 2029 and 2035
Table 28.63 Blood-Brain Barrier Penetrating Therapies Market for Intravenous Route of Administration: Forecasted Estimates (2024-2035) (USD Million)
Table 28.64 Blood-Brain Barrier Penetrating Therapies Market for Oral Route of Administration: Forecasted Estimates (2024-2035) (USDMillion)
Table 28.65 Blood-Brain Barrier Penetrating Therapies Market: Distribution by Target Indication, 2024, 2029 and 2035
Table 28.66 Blood-Brain Barrier Penetrating Therapies Market for Mucopolysaccharidosis Type II (Hunter Syndrome): Forecasted Estimates (2024-2035) (USD Million)
Table 28.67 Blood-Brain Barrier Penetrating Therapies Market for Multiple Sclerosis: Forecasted Estimates (2026-2035) (USD Million)
Table 28.68 Blood-Brain Barrier Penetrating Therapies Market for Amyotrophic Lateral Sclerosis: Forecasted Estimates (2028-2035) (USDMillion)
Table 28.69 Blood-Brain Barrier Penetrating Therapies Market for Leptomeningeal Carcinomatosis: Forecasted Estimates (2026-2035) (USDMillion)
Table 28.70 Blood-Brain Barrier Penetrating Therapies Market for Mucopolysaccharidosis Type III A (Sanfilippo Syndrome A): ForecastedEstimates (2028-2035) (USD Million)
Table 28.71 Blood-Brain Barrier Penetrating Therapies Market: Distribution by Therapeutics Area, 2024, 2029 and 2035
Table 28.72 Blood-Brain Barrier Penetrating Therapies Market for Lysosomal Storage Disorders: Forecasted Estimates (2024-2035) (USD Million)
Table 28.73 Blood-Brain Barrier Penetrating Therapies Market for Neurodegenerative Disorders: Forecasted Estimates (2026-2035) (USD Million)
Table 28.74 Blood-Brain Barrier Penetrating Therapies Market for Neuro-Oncology Disorders: Forecasted Estimates (2026-2035) (USD Million)
Table 28.75 Blood-Brain Barrier Penetrating Therapies Market: Distribution by Key Geographical Regions, 2024 and 2035 (USD Million)
Table 28.76 Blood-Brain Barrier Penetrating Therapies Market in North America: Forecasted Estimates (2026-2035) (USD Million)
Table 28.77 Blood-Brain Barrier Penetrating Therapies Market in Europe: Forecasted Estimates (2028-2035) (USD Million)
Table 28.78 Blood-Brain Barrier Penetrating Therapies Market in Asia-Pacific and RoW: Forecasted Estimates (2024-2035) (USD Million)
Table 28.79 Blood-Brain Barrier Penetrating Therapies Market: Izcargo / JR-141 / Pabinafusp Alfa Sales Forecast, 2024-2035 (USD Million)
Table 28.80 Blood-Brain Barrier Penetrating Therapies Market: ANG1005 / Paclitaxel Trevatide / GRN1005 Sales Forecast, 2026-2035 (USDMillion)
Table 28.81 Blood-Brain Barrier Penetrating Therapies Market: SAR-442168 / PRN2246 Sales Forecast, 2026-2035 (USD Million)
Table 28.82 Blood-Brain Barrier Penetrating Therapies Market: UX-111 / ABO-102 Sales Forecast, 2028-2035 (USD Million)
Table 28.83 Blood-Brain Barrier Penetrating Therapies Market: DNL310 / ETV: IDS Sales Forecast, 2026-2035 (USD Million)
Table 28.84 Blood-Brain Barrier Penetrating Therapies Market: DNL343 Sales Forecast, 2028-2035 (USD Million)

Companies Mentioned

  • ICBI
  • Denali Therapeutics
  • JCR Pharmaceuticals
  • Cyclenium Pharma
  • Lauren Sciences
  • biOasis Technologies
  • Ossianix
  • Angiochem
  • Genervon Biopharmaceuticals
  • NEUWAY Pharma
  • Tranquis Therapeutics
  • CERES BRAIN Therapeutics
  • Nanomerics
  • Reglagene

Methodology

 

 

Loading
LOADING...